Silence Therapeutics PLC - American Depository Share (SLN) closed at $19.66 on October 22, 2026, down 0.1% from the previous close, on volume of 3,045,083 shares (30-day average 3,837,324).
Data as of October 22, 2026.
Globe Newswire (Thu, 22-Oct 10:29 AM ET)
Business Wire (Wed, 21-Oct 3:35 PM ET)
Are BRZE, SLN, OPCH, RXO Obtaining Fair Deals for their Shareholders?
PRNewswire (Tue, 20-Oct 12:22 PM ET)
Business Wire (Mon, 19-Oct 9:40 AM ET)
Why Is Silence Therapeutics (SLN) Stock Up 125% Today?
TipRanks (Mon, 19-Oct 9:34 AM ET)
Market Chameleon (Mon, 19-Oct 5:10 AM ET)
Merck KGaA to buy Silence Therapeutics in all-cash deal
Seeking Alpha News (Mon, 19-Oct 8:20 AM ET)
Business Wire (Mon, 19-Oct 8:00 AM ET)
Silence Therapeutics Enters into Agreement to be Acquired by Merck KGaA, Darmstadt, Germany
Business Wire (Mon, 19-Oct 8:00 AM ET)
Silence Therapeutics to Participate in Three September Investor Conferences
Business Wire (Wed, 2-Sep 8:00 AM ET)
Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid or siRNA. Using its mRNAi GOLD platform, the company has generated siRNA product candidates both for its internal development pipeline as well as for out-licensed programs with third-party collaborators. Its wholly owned pipeline is focused on three therapeutic areas: cardiovascular disease, hematology, and rare diseases. The different product candidates in its pipeline are Divesiran (SLN124), a siRNA product candidate that has the potential to treat several hematological disorders; Zerlasiran (SLN360), being developed as a potential treatment to reduce cardiovascular issues; SLN-312; SLN-548; and multiple other programs.
Silence Therapeutics PLC - American Depository Share trades on the NASDAQ stock market under the symbol SLN.
As of October 22, 2026, SLN stock price declined to $19.66 with 3,045,083 million shares trading.
SLN has a beta of 1.90, meaning it tends to be more sensitive to market movements. SLN has a correlation of 0.07 to the broad based SPY ETF.
SLN has a market cap of $1.22 billion. This is considered a Small Cap stock.
Last quarter Silence Therapeutics PLC - American Depository Share reported $0 in Revenue and -$.09 earnings per share. This fell short of revenue expectation by $-1 million and exceeded earnings estimates by $.06.
In the last 3 years, SLN traded as high as $27.72 and as low as $1.97.
The top ETF exchange traded funds that SLN belongs to (by Net Assets): IBB, GWX, APIE, IBBQ, BIB.
SLN has outperformed the market in the last year with a price return of +165.7% while the SPY ETF gained +14.9%. SLN has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +81.2% and +100.2%, respectively, while the SPY returned +2.3% and -1.7%, respectively.
SLN support price is $18.78 and resistance is $20.56 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that SLN shares will trade within this expected range on the day.
